Promising cancer drugs may speed tumours in some patients.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

9 citing papers in PubMed.

1. Forefronts and hotspots evolution of the nanomaterial application in anti-tumor immunotherapy: a scientometric analysis.Journal of nanobiotechnology · 2024
   Article
2. Targeting immune checkpoints in gynecologic cancer: updates & perspectives for pathologists.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2022
   Review
3. Tumour growth rate as a tool for response evaluation during PD-1 treatment for non-small cell lung cancer: a retrospective analysis.ERJ open research · 2019
   Article
4. Emerging therapies for non-small cell lung cancer.Journal of hematology & oncology · 2019
   Review
5. Isolation and Identification of Cancer Stem-Like Cells in Adenocarcinoma and Squamous Cell Carcinoma of the Lung: A Pilot Study.Frontiers in oncology · 2019
   Article
6. Hyperprogressive disease in patients with non-small cell lung cancer treated with nivolumab: A case series.Thoracic cancer · 2018
   Article
7. Senescence-associated secretory factors induced by cisplatin in melanoma cells promote non-senescent melanoma cell growth through activation of the ERK1/2-RSK1 pathway.Cell death & disease · 2018
   Article
8. Hyperprogressive disease in patients with non-small cell lung cancer on immunotherapy.Journal of thoracic disease · 2018
   Review
9. Hyperprogressive Disease in Anorectal Melanoma Treated by PD-1 Inhibitors.Frontiers in immunology · 2018
   Article

Corrections and comments

• Comment on
  iRECIST: A clarification of tumour response assessment in the immunotherapy era.2017
• Comment on
  A novel c-abl protein product in Philadelphia-positive acute lymphoblastic leukaemia.

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as